Antiangiogenic therapy for von Hippel-Lindau disease

JAMA. 2004 Feb 25;291(8):943-4. doi: 10.1001/jama.291.8.943.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / therapeutic use*
  • Brain Neoplasms / drug therapy
  • Female
  • Hemangioblastoma / drug therapy
  • Humans
  • Indoles / therapeutic use*
  • Male
  • Middle Aged
  • Pyrroles / therapeutic use*
  • Retinal Neoplasms / drug therapy
  • Spinal Cord Neoplasms / drug therapy
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / blood
  • von Hippel-Lindau Disease / drug therapy*

Substances

  • Angiogenesis Inhibitors
  • Indoles
  • Pyrroles
  • Vascular Endothelial Growth Factor A
  • Semaxinib